Michael Gelband’s Astera Labs ALAB Stock Holding History

Michael Gelband’s Portfolio ALAB Stock Details ALAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-105,000	Closed	-$5.52M	–	2153
2024 Q3	$5.52M	Buy	+105,000	New	+$4.93M	0.03%	389

Other funds holding ALAB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Michael Gelband's ALAB Position: Q3 2025 in Review

Michael Gelband sold out of Astera Labs (ALAB) in Q3 2025, closing a stake of 100,632 shares — an estimated $9.1M sold.

Michael Gelband first reported a position in ALAB in Q3 2024 and held it in 2 quarters. The position peaked at $9.1M in Q2 2025. 659 funds tracked by Wall St. Rank hold ALAB as of Q3 2025.

Michael Gelband reported no remaining Astera Labs position as of Q3 2025 after selling out during the quarter.
Michael Gelband sold 100,632 Astera Labs shares in Q3 2025, an estimated $9.1M.
Michael Gelband first reported a position in Astera Labs in Q3 2024 and held it in 2 quarters.
Michael Gelband's Astera Labs position peaked at $9.1M in Q2 2025.
659 funds tracked by Wall St. Rank held Astera Labs as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.